Moderna’s Flu Shot Review Puts FDA Trust Back on the Clock
Reuters reported that the FDA will hold a June 18 advisory committee meeting to review Moderna’s experimental seasonal flu vaccine. The mRNA-based shot is under review after the agency initially rejected Moderna’s application, citing concerns about the standard-dose flu shot used in the comparison group. Reuters reported that the FDA later reversed course after meeting with the company and accepted an amended application, with Moderna promising an additional study in older adults if the vaccine is approved. A decision is expected by August 5. If approved, the vaccine would be the first seasonal flu shot in the United States made with mRNA technology, a faster platform than conventional flu vaccines. The regulatory backdrop is politically charged because Health Secretary Robert F. Kennedy Jr. has been a prominent critic of mRNA technology. The immediate question is Moderna’s flu shot. The larger question is whether FDA review can look transparent and evidence-driven in a climate where trust is already fragile.
The FDA’s review of Moderna’s flu vaccine is not just a pharma story. It is a trust story. Reuters reports that the agency will convene outside experts on June 18 to review an mRNA-based seasonal flu shot after an unusual back-and-forth: the FDA first rejected Moderna’s application, then accepted an amended version after the company agreed to conduct an additional study in older adults if the vaccine is approved. That procedural detail matters more than the stock-market reaction. It shows a regulator trying to move through a politically combustible area where every decision will be read as either capture or sabotage.
The public-health establishment has a problem it still does not fully understand. It cannot simply say “trust the science” and expect people to forget the last several years of institutional overstatement, policy whiplash and opaque messaging. At the same time, suspicion is not a substitute for evidence. A new flu vaccine should neither be rubber-stamped because it uses a modern platform nor buried because the platform became politically radioactive after COVID. The standard has to be boring, public and defensible: What did the trial show? What are the comparison concerns? What is known about older adults? What remains uncertain? What will the follow-up study actually answer?
That is why the advisory committee meeting matters. Public meetings are not magic, but they create a record. They force questions into the open. They make the agency explain why a prior rejection changed into an accepted amended application. In a healthier system, that would be normal regulatory iteration. In today’s environment, it will be interpreted through suspicion. Moderna’s supporters will say the science is being delayed by politics. Critics will say the company is being given another path because pharma influence never really loses. The FDA’s job is to make both claims less plausible by showing its work.
Luke’s lens fits because this is a structural-fragility story. Healthcare trust is capital. Once spent, it is expensive to rebuild. Every unclear FDA reversal, every poorly explained advisory process and every partisan health fight increases the cost of future public-health action. That cost does not show up only in vaccine uptake. It shows up in lawsuits, compliance delays, provider confusion, market volatility and the growing sense that health policy is just another political spoils system with medical language attached.
There is also a citizen-cost angle. Flu vaccination is not an abstract market. It affects employers, hospitals, older adults, insurers and families trying to avoid another seasonal wave of disruption. If mRNA technology can produce a better flu vaccine, the public has an interest in knowing that. If the evidence is not strong enough, the public has an interest in knowing that too. The regulator’s obligation is not to protect Moderna’s business model or validate Kennedy’s skepticism. It is to make the decision process legible.
The safest public position is not reflexive enthusiasm or reflexive distrust. It is insistence on transparent standards. The FDA should explain what changed after the first rejection, what the added older-adult study will and will not prove, and why the August decision should be viewed as evidence-based. That is how a health agency starts to rebuild credibility: not by demanding trust, but by making distrust harder to justify.